{'fraction_non_alphanumeric': 0.03716814159292035, 'fraction_numerical': 0.01327433628318584, 'mean_word_length': 4.860103626943006, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture].

Chemotherapy with FT-207 suppository (Futraful supo) for head and neck cancer was studied by Six Medical Schools in Kanagawa Prefecture, and its effectiveness and side effects were examined. Seventy-five cases were treated with this drug. However, thirty-four cases were used for the final evaluation, with regard to the given dose etc. Generally, the effectiveness rate was 23.5%. Thyroid cancer, nasal cancer and paranasal sinus cancer gave the best results. All four cases of adenocarcinoma showed an effect. One case, who was given a higher dose, showed an increased effect. Also, cases which has not been treated with any other therapeutic procedure previously, showed a significant effectiveness rate. Side effects were observed in 45.2% of cases. These were largely appetite loss and so on, which concerned the digestive system. On the whole, it has been proved that FT-207 suppository (Futraful Supo) is useful as an induction chemotherapeutic drug for head and neck cancer.